NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting
24 Abril 2024 - 9:43AM
NMDP℠, a global nonprofit leader in cell therapy, and
CIBMTR® (Center for International Blood and Marrow Transplant
Research®) will present new data on hematopoietic cell
transplantation (HCT) treatment effects in patients with
hematological malignancies at the American Society of Clinical
Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago,
Ill., and online. A chief focus will be sharing interim findings
from ACCESS, the prospective, multi-center, Phase II clinical trial
of HCT using human leukocyte antigen (HLA)-mismatched unrelated
donors (MMUD) for peripheral blood stem cell transplant in adults
and bone marrow stem cell transplant in children.
“New findings from the ACCESS study will advance broader
understanding of how mismatched unrelated donors can safely and
effectively address gaps in equitable access to transplant for
those patients who are unable to find a fully matched donor,” said
Steven M. Devine, M.D., Chief Medical Officer, NMDP; Senior
Scientific Director, CIBMTR. “Acceptance to present our collective
work is not only an honor, it’s a recognition that advancing the
evidence base for MMUD transplant for patients with blood cancers
and blood disorders remains of global importance to finding new
cures and saving more lives.”
CIBMTR is a research collaboration between the Medical College
of Wisconsin and NMDP, advancing research in cellular therapies to
improve patient outcomes.
ACCESS Trial Presentation
- Title: Post-transplant cyclophosphamide-based
graft-versus-host disease prophylaxis following mismatched
unrelated donor peripheral blood stem cell (PBSC)
transplantation
- Presenting Author: Monzr M.
Al Malki, M.D., Associate Professor, Department of Hematology &
Hematopoietic Cell Transplantation, City of Hope
- Session Type and Title: Oral Abstract;
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and
Allotransplant
- Abstract Number: 6503
- Date & Time: Friday, May 31; 2:45-5:45
p.m. CDT
- Location: S100bc
Additional CIBMTR Presentations
- Title: Safety outcomes in patients with acute
myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to
allogeneic hematopoietic stem cell transplantation
- Presenting Author: Partow Kebriaei, M.D., The
University of Texas MD Anderson Cancer Center
- Session Type and Title: Rapid Oral
Abstract; Hematologic Malignancies—Leukemia, Myelodysplastic
Syndromes, and Allotransplant
- Abstract Number: 6516
- Date & Time: Saturday, June 1; 8-9:30 a.m.
CDT
- Location: E450b
- Title: Identifying states for targeted alloHCT
access initiatives using social vulnerability, physician density,
and unmet need
- Presenting Author: Samantha Watters, Ph.D.,
MPH; NMDP
- Session Type and Title: Poster Abstract;
Care Delivery/Models of Care
- Abstract Number: 1528
- Date & Time: Saturday, June 1; 9 a.m. –
noon CDT
- Location: Hall A
- Title: Evolution of tisagenlecleucel use for
the treatment of pediatric and young adult relapsed/refractory
(r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for
International Blood & Marrow Transplant Research (CIBMTR)
registry results
- Presenting Author: Rayne H. Rouce, M.D.;
Associate Professor, Baylor College of Medicine; Texas Children’s
Cancer Center
- Session Title: Oral Abstract; Pediatric
Oncology II
- Abstract Number: 10016
- Date & Time: Monday, June 3; 11:30 a.m. –
2:30 p.m. CDT
- Location: S504
- Title: Safety outcomes in adult patients with
AML who achieved their first complete remission with GO prior to
HSCT
- Session Type and Title: ePublication
- Abstract Number: e18504
Full abstracts will be available at 4 p.m. CDT, May 23, 2024, on
the ASCO Annual Meeting website.
About the ACCESS Trial
ACCESS (NCT04904588) is a multi-center, Phase II study of
hematopoietic stem cell transplantation (HCT) using mismatched
unrelated donors (MMUD) for peripheral blood stem cell (PBSC)
transplant in adults and bone marrow stem cell transplant in
children. This trial completed enrollment in its adult arms ahead
of schedule and is continuing to enroll within its pediatric arm.
ACCESS aims to expand upon previous peer-reviewed findings of its
15-MMUD trial (NCT02793544) that showed encouraging three-year
outcomes in the use of post-transplant cyclophosphamide in MMUD
HCT, and a recent observational study that established no
discernable differences in graft-versus-host disease, relapse-free
survival or overall survival for patients who had a hematopoietic
cell transplant (HCT) with an 8/8 or 7/8 unrelated donor for adult
patients with hematologic malignancies.
About CIBMTR®
CIBMTR® (Center for International Blood and Marrow Transplant
Research®) is a nonprofit research collaboration between NMDP℠, in
Minneapolis, and the Medical College of Wisconsin, in Milwaukee.
CIBMTR collaborates with the global scientific community to
increase survival and enrich quality of life for patients. CIBMTR
facilitates critical observational and interventional research
through scientific and statistical expertise, a large network of
centers, and a unique database of long-term clinical data for more
than 630,000 people who have received hematopoietic cell
transplantation and other cellular therapies. Learn more
at cibmtr.org.About NMDP℠
At NMDP℠, we believe each of us holds the key to curing blood
cancers and disorders. As a global nonprofit leader in cell
therapy, NMDP creates essential connections between researchers and
supporters to inspire action and accelerate innovation to find
life-saving cures. With the help of blood stem cell donors from the
world’s most diverse registry and our extensive network of
transplant partners, physicians and caregivers, we’re expanding
access to treatment so that every patient can receive their
life-saving cell therapy. NMDP. Find cures. Save
lives. Learn more at nmdp.org.
Contact:
Jess Ayersmedia@nmdp.org